CBL Chemical Biology Lab

Neuromyelitis Optica

(NMO)

In collaboration with:

  • Toscana Biomarkers Srl, Siena, Italy
  • Neurologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, France
  • LINC, Université de Strasbourg-CNRS, France

 

In NMO, an autoimmune disease of the central nervous system, anti-aquaporin 4 antibodies are currently the only available immunological markers, although they are not detected in 10–50% of patients. Using enzyme-linked immunosorbent assays, we evaluated the reactivity against 19 structurally defined peptides in 26 NMO sera compared with 21 healthy subjects. We observed increased levels of IgG against the myelin basic protein sequence MBP(156–175), the pyruvate dehydrogenase sequence PDH(167–186), and the N-glucosylated beta-turn peptide CSF114(Glc), the last of these having a possible correlation with onset of inflammatory relapse. These preliminary results may suggest that the aquaporin 4 is not the unique target in NMO and that the study of reactivity against these peptides would be helpful for the diagnosis and follow-up of the disease.

 

Evaluation of new immunological targets in neuromyelitis optica. Chanson, J.-B.; Paolini, I.; Collongues, N.; Alcaro, M. C.; Blanc, F.; Barbetti, F.; Fleury, M.; Peroni, E.; Rovero, P.; Rudolf, G.; Lolli, F.; Trifilieff, É.; Papini, A.-M.; De Seze, J. J. Peptide Sci. 2013, 19, 25–32.

 

 

Share: